©2022 Stanford Medicine
Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer
Not Recruiting
Trial ID: NCT04389918
Purpose
This study will find out if a meal replacement of this type is satisfying and tolerable for
men with prostate cancer. Participants will receive meal replacements of TalityTM as their
expected sole source of nutrition for 4 weeks. The purpose of the study is to test whether
TalityTM Synthetic Meal Replacements are suitable to be used in larger studies of patients
with prostate or other types of cancer.
Official Title
A Phase I Study of the Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Patients With Prostate Cancer
Stanford Investigator(s)
Randall Stafford
Professor of Medicine (Stanford Center for Research in Disease Prevention)
Alice C. Fan
Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- Biopsy-proven prostate cancer with stable or rising PSA levels, defined as three
consecutive PSA levels, each value greater than 1 week apart, with fluctuation between
the three values no more than 10% downward. The third PSA needs to be within 30 days
prior to enrollment and >= 0.1.
- Patients may previously have been on any regimen of chemotherapy completed at least
one month prior. Patients may be on any stable form of anti-androgen therapy.
- Males >= age 18.
- All patients must have a life expectancy of > 6 months.
- Patients must have an ECOG Performance Status of <= 1
- Patients must have no clinically significant abnormalities of organ or bone marrow
function
- Patients must have the ability to understand and the willingness to sign a written
informed consent document, and the willingness/ability to comply with the protocol
activities.
Exclusion Criteria:
- Chemotherapy within one month prior to enrollment or plans to receive chemotherapy
within one month after enrollment. Patients who are expected to require new or
modified anti-androgen therapy during the course of the study are also excluded.
- Patients may not be receiving any other Investigational Agents during the course of
the study.
- Patients who experience frequent symptoms of a gastrointestinal nature (e.g.,
diarrhea, abdominal bloating, constipation or pain) are excluded.
- Known CNS metastases.
- Patients who, in the opinion of the Principal Investigator, have a clinically
significant co-morbid disease that is likely to affect the ability of the patient to
complete the trial, interfere with their ability with measurement of self-reported
outcomes or result in adverse events unrelated to TalityTM are excluded.
- Patients with a history of food allergy are excluded.
- Concomitant medications necessary to treat baseline disorders are allowed (e.g.,
hypertension, diabetes, and hyperlipidemia).
- Patients requiring concomitant medications that, in the opinion of the Principal
Investigator, have an unacceptable risk of adverse effects due to their nature (e.g.,
anti-coagulant therapy, immuno-modulatory agents for autoimmune disease) must be
excluded.
- Pregnant or nursing patients will not be enrolled since prostate cancer is limited to
males.
- HIV-positive patients with active infections, HIV related cancer or poorly controlled
viral loads must be excluded. HIV-positive patients who are stable on anti-viral
therapy may be enrolled.
Intervention(s):
other: Tality
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Deirdre Crommie
650-387-7797